Sign In
Buy FULC
$3.58
-0.140 (-3.76%)
At Close: Jul 31, 2026
Kaplan Fox Reminds Fulcrum Therapeutics, Inc. (FULC) Investors of an Investigation into Potential Securities Law Violations
10:45am, Friday, 31'st Jul 2026
New York, New York--(Newsfile Corp. - July 31, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "C
Fulcrum Therapeutics: Buy It For The Strategic Reset
08:13am, Friday, 31'st Jul 2026
Fulcrum is trading at a deep discount due to operational distress after the suspension of their main program. But because of their fortress balance sheet, Fulcrum should have the financial strength to
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Securities Investigation into the Company
10:30am, Wednesday, 29'th Jul 2026
New York, New York--(Newsfile Corp. - July 29, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "C
New York, New York--(Newsfile Corp. - July 27, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "C
New York, New York--(Newsfile Corp. - July 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "C
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (FULC) Investors to an Investigation of Potential Securities Law Violations
12:00pm, Monday, 20'th Jul 2026
New York, New York--(Newsfile Corp. - July 20, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "C
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "C
Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky
09:00am, Tuesday, 09'th Jun 2026
Fulcrum Therapeutics, Inc. stock lost roughly half its value after the FDA flagged class-wide safety concerns about the entire PRC2 inhibitor drug class -- forcing immediate discontinuation of pocired
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Friday, 05'th Jun 2026
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC)
09:00am, Friday, 05'th Jun 2026
Fulcrum Therapeutics, Inc. stock lost roughly half its value in a single session after the company disclosed FDA safety concerns that forced discontinuation of its lead sickle-cell candidate Fulcrum T
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud
02:53pm, Thursday, 04'th Jun 2026
NEW YORK--(BUSINESS WIRE)--Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PR
What's Going On With Fulcrum Therapeutics Stock On Thursday?
10:22am, Thursday, 04'th Jun 2026
Fulcrum Therapeutics Inc. (NASDAQ:FULC) shares are up on Thursday as the company faces significant challenges following its decision to discontinue pociredir, its lead experimental drug for sickle cel
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
12:01pm, Wednesday, 03'rd Jun 2026
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations
09:00am, Wednesday, 03'rd Jun 2026
SEC filings reflected insider equity holdings and awards totaling more than 264,000 shares NEW YORK, June 3, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) lost approximately 50% of it
Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 million facility lease locked the company into infrastructure now stranded by program termination. NEW
